The bioidentical hormone debate: Are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?

Postgraduate Medicine

Volumn 121, Issue 1, 2009, Pages 73-85

  Holtorf, Kent ^a  

^a Holtorf Medical Group Inc   (United States)

Author keywords

Bioidentical hormones; Breast cancer; Cardiovascular disease; Conjugated equine estrogens; Eslriol; Hormone replacement therapy; Medroxyprogesterone acetate; Progesterone; Synthetic hormones

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTRADIOL VALERATE; ESTRIOL; ESTROGEN; ESTRONE; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; PROGESTERONE; TAMOXIFEN; ESTRADIOL DERIVATIVE;

ARTICLE; BREAST; BREAST CANCER; BREAST TENDERNESS; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COCHRANE LIBRARY; CONTINUOUS INFUSION; DEPRESSION; DRUG CARCINOGENICITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HEART INFARCTION; HORMONE ACTION; HORMONE STRUCTURE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; MEDLINE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SATISFACTION; RISK ASSESSMENT; SEARCH ENGINE; SIDE EFFECT; SLEEP DISORDER; STROKE; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; ESTROGEN THERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; ESTRADIOL; ESTRADIOL CONGENERS; ESTRIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; PATIENT SATISFACTION; PROGESTERONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 60549097528     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.01.1949     Document Type: Article

References (196)

1. The Endocrine Society. Bioidentical Hormones Position Statement, October 2006. http:/www.endo-society.org/publicpolicy/policy/upload/BH-Position- Statement-final-10-25-06-w-Header.pdf. Accessed January 21, 2008.
2. Fitzpatrick LA, Pace C, Witta B. Comparison of regimens containing oral micronized progesterone of medroxyprogesterone acetate on quality of life in postmenopausal women: a cross-sectional survey. J Womens Health Gend Based Med. 2000;9(4):381-387. (Pubitemid 30411749)
3. Cummings JA, Brizendine L. Comparison of physical and emotional side effects of progesterone or medroxyprogesterone in early postmenopausal women. Menopause. 2002;9:253-263. (Pubitemid 34743450)
4. Lindenfeld EA, Langer RD. Bleeding patterns of the hormone replacement therapies in the postmenopausal estrogen and progestin interventions trial. Obstet Gynecol. 2002;100(5 pt 1):853-863. (Pubitemid 35387450)
5. Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol. 1998;92(6):982-988. (Pubitemid 28536116)
6. Hargrove JT, Maxon WS, Wentz AC, Burnett LS. Menopausal hormone replacement therapy with continuous daily oral mircronized progesterone. Obstet Gynecol. 1989;73(4):606-612. (Pubitemid 19086973)
7. de Lignières B. Effects of progestogens on the postmenopausal breast. Climacteric. 2002;5(3):229-235.
8. Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol. 2005;96(2):95-108. (Pubitemid 41096673)
9. Ory K, Lebeau J, Levalois C, et al. Apoptosis inhibition mediated by medroxyprogesterone acetate treatment of breast cancer cell lines. Breast Cancer Res Treat. 2001;68(3):187-198. (Pubitemid 33702315)
10. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxy-progesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab. 1999;84(12):4559-4565.
11. Jeng MH, Parker CJ, Jordan VC. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res. 1992;52(23):6539-6546.
12. Kalkhoven E, Kwakkenbos-Isbrücker L, de Laat SW, van der Saag PT, van der Burg B. Synthetic progestins induce proliferation of breast tumor cell lines via the progesterone or estrogen receptor. Mol Cell Endocrinol. 1994;102(1-2):45-52. (Pubitemid 24177476)
13. Papa V, Reese CC, Brunetti A, Vigneri R, Siiteri PK., Goldfine ID. Progestins increase insulin receptor content and insulin stimulation of growth in human breast carcinoma cells. Cancer Res. 1990;50(24):7858-7862.
14. Hissom JR, Moore MR. Progestin effects on growth in the human breast cancer cell line T-47D possible therapeutic implications. Biochem Biophys Res Commun. 1987;145(2):706-711. (Pubitemid 17093511)
15. Catherino WH, Jeng MH, Jordan VC. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer. 1993;67(5):945-952. (Pubitemid 23147484)
16. Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat. 2007;101(2):125-134. (Pubitemid 46115419)
17. Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques. Breast Cancer Res Treat. 1998;48(3):221-229. (Pubitemid 28159950)
18. Cline JM, Soderqvist G, von Schoultz L, Skoog L, von Schoultz B. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol. 1996;174(1 pt 1):93-100. (Pubitemid 26037695)
19. Braunsberg H, Coldham NG, Wong W. Hormonal therapies for breast cancer: can progestogens stimulate growth? Cancer Lett. 1986;30(2):213-218. (Pubitemid 16152817)
20. van der Burg B, Kalkhoven E, Isbrücker L, de Laat SW. Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells undergrowth factor-defined conditions. J Steroid Biochem Mol Biol. 1992;42(5):457-465.
21. Saitoh M, Ohmichi M, Takahashi K, et al. Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-kappaB cascade in human breast cancer cells. Endocrinology. 2005;146(11):4917-4925. (Pubitemid 41446630)
22. Chang KJ, Lee TY, Linares-Cruz G, Fournier S, de Ligniéres B, Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril. 1995;63(4):785-791.
23. Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril. 1998;69(5):963-969. (Pubitemid 28193936)
24. Mueck AO, Seeger H, Wallwiener D. Comparison of proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition. Climacteric. 2003;6(3):221-227. (Pubitemid 37188282)
25. Inoh A, Kamiya K, Fujii Y, Yokoro K. Protective effects of progesterone and tamoxifen in estrogen induced mammary carcinogenesis in ovariectomized W/Fu rats. Jpn J Cancer Res. 1985;76(8):699-704. (Pubitemid 15232454)
26. Barrat J, de Lignieres B, Marpeau L, et al. Effect in vivo de l'adminstration locale de progesterone sur l'activite mitotique des glaactophores humains. [The in vivo effect of the local administration of progesterone on the mitotic activity of human ductal breast tissue. Results of a pilot study.] J Gynecol Obstet Biol Reprod (Paris). 1990;19(3):269-274.
27. Malet C, Spritzer P, Guillaumin D, Kuttenn F. Progesterone effect on cell growth, ultrastructural aspect and estradiol receptors of normal breast epithelial (HBE) cells in culture. J Steroid Biochem Mol Biol. 2000;73(3-4):171-181. (Pubitemid 30488098)
28. Mauvais-Jarvis P, Kuttenn F, Gompel A. Antiestrogen action of progesterone in breast tissue. Breast Cancer Res Treat. 1986;8(3):179-188. (Pubitemid 17073477)
29. Soderqvist G, von Schoultz B, Tani E, Skoog L. Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle. Am J Obstet Gynecol. 1993;168(3 pt 1):874-879. (Pubitemid 23096012)
30. Formby B, Wiley TS. Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53. Ann Clin Lab Sci. 1998;28(6):360-369. (Pubitemid 28541694)
31. Formby B, Wiley TS. Bcl-2, survivin and variant CD44 v7-v10 are downregulated and p53 is upregulated in breast cancer cells by progesterone: inhibition of cell growth and induction of apoptosis. Mol Cell Biochem. 1999;202(1-2):53-61. (Pubitemid 30099738)
32. Groshong SD, Owen GI, Grimison B, et al. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol. 1997;11(11):1593-1607. (Pubitemid 27435408)
33. Segaloff A. Inhibition by progesterone of radiation-estrogen-induced mammary cancer in the rat. Cancer Res. 1973;33(5):1136-1137.
34. Schmidt M, Renner C, Löffler G. Progesterone inhibits glucocorticoid-dependent aromatase induction in human adipose fibroblasts. J Endocrinol. 1998;158(3):401-407. (Pubitemid 28407547)
35. Jordan VC, Jeng MH, Catherino WH, Parker CJ. The estrogenic activity of synthetic progestins used in oral contraceptives. Cancer. 1993;71(4 suppl):1501-1505. (Pubitemid 23056066)
36. Botella J, Duranti E, Viader V, Duc I, Delansorne R, Paris J. Lack of estrogenic potential of progesterone- or 19-nor-progesterone-derived progestins as opposed to testosterone or 19-nor-testosteorne derivatives on endometrial Ishikawa cells. J Steroid Biochem Mol Biol. 1995;55(1):77-84.
37. Botella J, Duc I, Delansorne R, Paris J, Lalilou B. Regulation of rat uterine steroid receptors by nomegestrol acetate, a new 19-nor-progesterone derivative. J Pharmacol Exp Ther. 1989;248(2):758-761. (Pubitemid 19090251)
38. Markiewicz L, Hochberg RB, Gurpide E. Intrinsic estrogenicity of some progestogenic drugs. J Steroid Biochem Mol Biol. 1992;41(1):53-58.
39. Rabe T, Bohlmann MK, Rehberger-Schneider S, Prifti S. Induction of estrogen receptor-alpha and -beta activities by synthetic progestins. Gynecol Endocrinol. 2000;14(2):118-126. (Pubitemid 30307220)
40. Campagnoli C, Abba C, Ambroggio S, Peris C. Pregnancy, progesterone and progestins in relation to breast cancer risk. J Steroid Biochem Mol Biol. 2005;97(5):441-450. (Pubitemid 41691885)
41. Seeger H, Mueck AO, Lippert TH. Effect of norethisterone acetate on estrogen metabolism in postmenopausal women. Horm Metab Res. 2000;32(10):436-439.
42. Coldham NG, James VH. A possible mechanism for increased breast cell proliferation by progestins through increased reductive 17 beta-hydroxysteroid dehydrogenase activity. Int J Cancer. 1990;45(1):174-178. (Pubitemid 20032117)
43. Xu B, Kitawaki J, Koshiba H, et al. Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells. Maturitas. 2007;56(2):142-152. (Pubitemid 46073512)
44. Prost-Avallet O, Oursin J, Adessi GL. In vitro effect of synthetic progestogens on estrone sulfatase activity in human breast carcinoma. J Steroid Biochem Mol Biol. 1991;39(6):967-973.
45. Pasqualini JR. Differential effects of progestins on breast tissue enzymes. Maturitas. 2003;46:45-54. (Pubitemid 37506062)
46. Pollow K, Boquoi E, Baumann J, Schmidt-Gollwitzer M, Pollow B. Comparison of the in vitro conversion of estradiol-17 beta to estrone of normal and neoplastic human breast. Mol Cell Endocrinol. 1977;6(4-5):333-348.
47. Fournier S, Kuttenn F, de Cicco F, Baudot N, Malet C, Mauvais-Jarvis P. Estradiol 17 beta-hydroxysteroid dehydrogenase activity in human breast fibroadenomas. J Clin Endo Metab. 1982;55(3):428-433. (Pubitemid 13242167)
48. Giangrande PH, Kimbrel EA, Edwards DP, McDonnell DP. The opposing transcriptional activities of the two isofonns of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol. 2000;20(9):3102-3115. (Pubitemid 30215023)
49. Wei LL, Gonzalez-Aller C, Wood WM, Miller LA, Horwitz KB. 5′-Heterogeneity in human progesterone receptor transcripts predicts a new amino-terminal truncated "C"-receptor and unique A-receptor messages. Mol Endocrinol. 1990;4(12):1833-1840.
50. Mote PA, Bartow S, Tran N, Clarke CL. Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat. 2002;72(2):163-172. (Pubitemid 34407211)
51. Graham JD, Clarke C. Expression and transcriptional activity of progesterone receptor A and progesterone receptor B in mammalian cells. Breast Cancer Res. 2002;4(5):187-190. (Pubitemid 34918996)
52. Kastner P, Krust A, Turcotte B, et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 1990;9(5):1603-1614. (Pubitemid 20137018)
53. Mote P, Clarke C. Relative expression of progesterone receptors A and B in premalignant and invasive breast lesions. Breast Cancer Res. 2000;2(suppl 1):P2.01.
54. Hopp TA, Weiss HL, Hilsenbeck SG, et al. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004;10(8):2751-2760. (Pubitemid 38509151)
55. Isaksson E, Wang H, Sahlin L, von Schoultz B, Cline JM, von Schoultz E. Effects of long-term HRT and tamoxifen on the expression of progesterone receptors A and B in breast tissue form surgically postmenopausal cynomolgus macaques. Breast Cancer Res Treat. 2003;79(2):233-239. (Pubitemid 36649173)
56. Vereide AB, Kaino T, Sager G, Arnes M, Ørbo A. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. Gynecol Oncol. 2006;101(2):214-223.
57. Custodia-Lora N, Novillo A, Callard IP, Regulation of hepatic progesterone and estrogen receptors in the female turtle, Chrysemys picta: relationship to vitellogenesis. Gen Comp Endocrinol. 2004;136(2):232-240. (Pubitemid 38340786)
58. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005;114:448-454. (Pubitemid 40279968)
59. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103-111. (Pubitemid 350179584)
60. Peck JD, Hulka BS, Poole C, Savitz DA, Baird D, Richardson BE. Steroid hormone levels during pregnancy and incidence of maternal breast cancer. Cancer Epidemiol Biomarkers Prev. 2002;11(4):361-368. (Pubitemid 34408215)
61. Micheli A, Muti P, Secreto G, et al. Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer. 2004;112(2):312-318. (Pubitemid 39244371)
62. Gottardis M, Ertürk E, Rose DP. Effects of progesterone administration on N-nitrosomethylurea-induced rat mammary carcinogenesis. Eur J Cancer Clin Oncol. 1983;19(10):1479-1484.
63. Grubbs CJ, Farnell DR, Hill DL, MeDonough KC. Chemoprevention of N-nitroso-N-methylurea induced mammary cancers by pretreatment with 17 beta-estradiol and progesterone. J Natl Cancer Inst. 1985;74(4):927-931, (Pubitemid 15118254)
64. Kledzik GS, Bradley CJ, Meites J. Reduction of carcinogen-induced mammary cancer incidence in rats by early treatment with hormones or drugs. Cancer Res, 1974;34(11):2953-2956.
65. Welsch CH, Clemens JA, Meites J. Effects of multiple pituitary homografts or progesterone on 7,12-dimethylbenz[a]anthracene-induced mammary tumors in rats. J Natl Cancer Inst. 1968;41(2):465-478.
66. Bernstein L, Yuan JM, Ross RK, et al. Serum hormone levels in pre-menopausal Chinese women in Shanghai and white women in Los Angeles: results from two breast cancer case-control studies. Cancer Causes Control. 1990;1(1):51-58.
67. Drafta D, Schindler AE, Milcu SM, et al. Plasma hormones in pre- and postmenopausal breast cancer. J Steroid Biochem. 1980;13(7):793-802. (Pubitemid 11223926)
68. Malarkey WB, Schroeder LL, Stevens VC, James AG, Lanese RR. Twenty-four-hour preoperative endocrine profiles in women with benign and malignant breast disease. Cancer Res. 1977;37(12):4655-4659. (Pubitemid 8239677)
69. Meyer F, Brown JB, Morrison AS, MacMahon B. Endogenous sex hormones, prolactin, and breast cancer in premenopausal women. J Natl Cancer Inst. 1986;77(3):613-616. (Pubitemid 16016575)
70. Secreto G, Toniolo P, Berrino F, et al. Increased androgenic activity and breast cancer risk in premenopausal women. Cancer Res. 1984(12 pt 1); 44:5902-5905. (Pubitemid 15183608)
71. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
72. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712. (Pubitemid 38489892)
73. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003;289(24):3243-3253. (Pubitemid 37430077)
74. Porch JV, Lee IM, Cook NR, Rexrode KM, Burin JE. Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Causes Control. 2002;13(9):847-854. (Pubitemid 35305204)
75. Lee SA, Ross RK, Pike MC. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer. 2005;92(11):2049-2058. (Pubitemid 40897429)
76. Ewertz M, Mellemkjaer L, Poulsen AH, et al. Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer. 2005;92(7):1293-1297. (Pubitemid 40604407)
77. Newcomb PA, Titus-Ernstoff L, Egan KM, et al. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epid Bio Prev. 2002;11(7):593-600. (Pubitemid 34760816)
78. Stahlberg C, Pedersen AT, Lynge E, et al. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer. 2004;109(5):721-727. (Pubitemid 38405620)
79. Li CI. Postmenopausal hormone therapy and the risk of breast cancer: the view of an epidemiologist. Maturitas. 2004;49(1):44-50. (Pubitemid 39209370)
80. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin- replacement therapy. Int J Cancer. 1999;81(3):339-344. (Pubitemid 29165190)
81. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Estrogen-progestin replacement and risk of breast cancer. JAMA. 2000;284(6):691-694.
82. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000;92(4):328-332. (Pubitemid 30117736)
83. Warren MP. A comparative review of the risks and benefits of hormone replacement therapy regimens. Am J Obstet Gynecol. 2004;190(4):1141-1167. (Pubitemid 38561539)
84. Weiss LK, Burkman RT, Cushing-Haugen KL, et al. Hormone replacement therapy regimens and breast cancer risk(1). Obstet Gynecol. 2002;100(6):1148- 1158. (Pubitemid 35449180)
85. Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA. 2003;289(24):3254-3263. (Pubitemid 37430078)
86. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419-427. (Pubitemid 36999703)
87. Kirsh V, Kreiger N. Estrogen and estrogen progestin replacement therapy and risk of postmenopausal breast cancer in Canada. Cancer Causes Control. 2002;13(6):583-590. (Pubitemid 34833110)
88. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1997;350(9084):1047-1059.
89. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 2000;283(4):485-491. (Pubitemid 30062864)
90. Colditz G, Rosner B. Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone. Am J Epidemiol. 1998;147:S45.
91. Persson I, Weiderpass E, Bergkvist L, Bergström R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control. 1999;10(4):253-260. (Pubitemid 29358958)
92. Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287(6):734-741. (Pubitemid 34250459)
93. Pike MC, Ross RK. Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids. 2000;65(10-11-):659-664.
94. Santen RJ, Pinkerton J, McCartney C, Petroni GR. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab. 2001;86(1):16-23. (Pubitemid 32109768)
95. Stahlberg C, Pederson AT, Lynge E, Ottesen B. Hormone replacement therapy and risk of breast cancer: the role of progestins. Acta Obstet Gynecol Scand. 2003;82(7):335-344. (Pubitemid 36570717)
96. Olsson HL, Ingvar C, Bladström A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer. 2003;97(6):1387-1392. (Pubitemid 36297767)
97. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332(24):1589-1593.
98. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol. 2000;152(10):950-964.
99. Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol. 1981;114(2):209-217. (Pubitemid 11051954)
100. Badwe RA, Wang DY, Gregory WM, et al. Serum progesterone at the time of surgery and survival in women with premenopausal operable breast cancer. Eur J Cancer. 1994;30A(4):445-448. (Pubitemid 24171947)
101. Mohr PE, Wang DY, Gregory WM, Richards MA, Fentiman IS. Serum progesterone and prognosis in operable breast cancer. Br J Cancer. 1996;73(12):1552-1555. (Pubitemid 26235382)
102. Veronese SM, Gambacorta M. Detection of Ki-67 proliferation rate in breast cancer. Correlation with clinical and pathologic features. Am J Clin Pathol. 1991;95(1):30-34.
103. Innes KE, Byers TE. First pregnancy characteristics and subsequent breast cancer risk among young women. Int J Cancer. 2004;112(2):306-311. (Pubitemid 39263739)
104. Troisi R, Weiss HA, Hoover RN, et al. Pregnancy characteristics and maternal risk of breast cancer. Epidemiology. 1998;9(6):641-647. (Pubitemid 28476126)
105. Vatten LJ, Romundstad PR, Trichopoulos D, Skjærven R. Pre-eclampsia in pregnancy and subsequent risk for breast cancer. Br J Cancer. 2002;87(9):971-973. (Pubitemid 35305647)
106. Paruthiyil S, Parma H, Kerekatte V, Cunha GR, Firestone GL, Lehman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cycle arrest. Cancer Res. 2004;64(1):423 428. (Pubitemid 38114127)
107. Paech K, Webb P, Kuiper GG, et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sties. Science. 1997;277(5331):1508-1510. (Pubitemid 27449239)
108. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A. 1996;93(12):5925-5930. (Pubitemid 26190778)
109. Green S, Walter P, Greene G, et al. Cloning of the human oestrogen receptor cDNA. J Steroid Biochem. 1986;24(1):77-83. (Pubitemid 16047760)
110. Katzenellenbogen BS, Montano MM, Ediger TR, et al. Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Prog Horm Res. 2000;55:163-193. (Pubitemid 32094449)
111. Nilsson S, Mäkelä S, Treuter E, et al. Mechanisms of estrogen action. Physiol Rev. 2001;81(4):1535-1565. (Pubitemid 32951806)
112. Helguero LA, Faulds MH, Gustafsson JA, Haldosén LA. Estrogen receptors alpha (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene. 2005;24(44):6605-6616. (Pubitemid 41486791)
113. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer. 2004;11(3):537-551. (Pubitemid 39331282)
114. Isaksson E, Wang H, Sahlin L, et al. Expression of estrogen receptors (alpha, beta) and insulin-like growth factor-1 in breast tissue form surgically postmenopausal cynomolgus macaques after long-term treatment with HRT and tamoxifen. Breast. 2002;11(4):295-300. (Pubitemid 35189527)
115. Weatherman RV, Clegg NJ, Scanlan TS. Differential SERM activation of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites. Chem Biol. 2001;8(5):427-436. (Pubitemid 32455897)
116. Pettersson K, Delaunay F, Gustafsson JA. Estrogen receptor beta acts a dominant regulator of estrogen signaling. Oncogene. 2000;19(43):4970-4978.
117. Saji S, Jensen EV, Nilsson S, Rylander T, Warner, Gustafsson JA. Estrogen receptors alpha and beta in the rodent mammary gland. Proc Natl Acad Sci U S A. 2000;97(1):337-342. (Pubitemid 30055832)
118. Zhu BT, Han GZ, Shim JY, Wen Y, Jiang XR. Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding. Endocrinology. 2006;147(9):4132-4150. (Pubitemid 44274976)
119. Rich RL, Hoth LR, Geoghegan KF, et al. Kinetic analysis of estrogen receptor/figand interactions. Proc Natl Acad Sci U S A. 2002;99(13):8562-8567. (Pubitemid 34693601)
120. Ekena K, Katzenellenbogen JA, Katzenellenbogen BS. Determinants of ligand specificity of estrogen receptor-alpha: estrogen versus androgen discrimination. J Biol Chem. 1998;273(2):693-699. (Pubitemid 28049154)
121. Hanstein B, Liu H, Yancisin MC, Brown M. Functional analysis of a novel estrogen receptor-beta isoform. Mol Endocrinol. 1999;13(1):129-137. (Pubitemid 29022285)
122. Lemon HM. Pathophysiologic considerations in the treatment of menopausal patients with oestrogens; the role of oestriol in the prevention of mammary carcinoma. Acta Endocrinol Suppl (Copenh). 1980;233:17-27. (Pubitemid 11238084)
123. Lemon HM, Kumar PF, Peterson C, Rodriguez-Sierra JF, Abbo KM. Inhibition of radiogenic mammary carcinoma in rats by estriol or tamoxifen. Cancer. 1989;63(9):1685-1692. (Pubitemid 19110604)
124. Lemon HM. Estriol prevention of mammary carcinoma induced by 7,12-dimethylbenzanthracene and procarbazine. Cancer Res. 1975;35(5):1341-1353.
125. MacMahon B, Cole P, Brown JB, et al. Oestrogen profiles of Asian and North American women. Lancet. 1971;2(7730):900-902.
126. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. Differential response of estrogen receptor alpha and receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol. 1998;54(1):105-112. (Pubitemid 28337592)
127. Pisha E, Lui X, Constantinou AI, Bolton JL. Evidence that a metabolite of equine estrogens, 4-hydroxequilenin, induces cellular transformation in vitro. Chem Res Toxicol. 2001;14(1):82-90. (Pubitemid 32064378)
128. Zhang F, Chen Y, Pisha E, et al. The major metabolite of equilin, 4-hyroxyequilin, autoxidizes to an o-quinone with isomerizes to the potent cytotoxin 4-hydroyequilenin-o-quinone. Chem Res Toxicol. 1999;12(2):204-213. (Pubitemid 29096070)
129. Chen Y, Liu X, Pisha E, et al. A metabolite of equine estrogens, 4-hydroxyequilenin, induces DNA damage and apoptosis in breast cancer cell lines. Chem Res Toxicol. 2000;13(5):342-350. (Pubitemid 30327153)
130. Zhang F, Swanson SM, van Breemen RB, et al. Equine estrogen metabolite 4-hydroxyequilenin induces DNA damage in the rat mammary tissues: formation of single-strand breaks, apurinic sites, stable adducts, and oxidized bases. Chem Res Toxicol. 2001;14(12):1654-1659. (Pubitemid 34016629)
131. Shen L, Qiu S, Chen Y, et al. Alkylation of 2′-deoxynucleosides and DNA by the Premarin metabolite 4-hydroxyequilenin semiquinone radical. Chem Res Toxicol. 1998;11(2):94-101. (Pubitemid 28128440)
132. Gross J, Modan B, Bertini B, et al. Relationship between steroid excretion patterns and breast cancer incidence in Israeli women of various origins. J Natl Cancer Inst. 1997;59(1):7-11.
133. Cole P, MacMahon B. Oestrogen fractions during early reproductive life in the aetiology of breast cancer. Lancet. 1969;1(7595):604-606.
134. Dickinson LE, MacMahon B, Cole P, Brown JB. Estrogen profiles of Oriental and Caucasian women in Hawaii. N Engl J Med. 1974;291(23):1211-1213.
135. Melamed M, Castaño E, Notides AC, Sasson S. Molecular and kinetic basis for the mixed agonist/antagonist activity of estriol. Mol Endocrinol. 1997;11(12):1868-1878. (Pubitemid 27467765)
136. Speroff L. The breast as an endocrine target organ. Contemp Obstet Gynec. 1977;9:69-72.
137. Rosner B, Colditz, GA, Willelt WC. Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Am J Epidemiol. 1994;139(8):819-835. (Pubitemid 24135786)
138. Russo J, Tay LK, Russo IH. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat. 1982;2(1):5-73. (Pubitemid 12017450)
139. Pasqualini JR. The fetus, pregnancy, and breast cancer. In: Pasqualini JR, ed. Breast Cancer: Prognosis, Treatment, and Prevention. New York, NY: Marcel Dckkcr Inc; 2002:19-71.
140. Vatten LJ, Romundstad PR, Trichopoulos D, Skjærven R. Pregnancy related protection against breast cancer depends on length of gestation. Br J Cancer. 2002;87(3):289-290. (Pubitemid 34888579)
141. Ekbom A, Hsieh CC, Lipworth L, Adami HQ, Trichopoulos D. Intra-uterine environment and breast cancer risk in women: a population-based study. J Natl Cancer Inst. 1997;89(1):71-76. (Pubitemid 26428080)
142. Ursin G, Wilson M, Henderson BE, et al. Do urinary estrogen metabolites reflect the differences in breast cancer risk between Singapore Chinese and United States African-American and white women? Cancer Res. 2001;61(8):3326- 3329. (Pubitemid 32695021)
143. Lemon HM. Genetic predisposition to carcinoma of the breast: multiple human genotypes for estrogen 16 alpha hydroxylase activity in Caucasians. J Surg Oncol. 1972;4(3):255-273.
144. Bakken K, Alsaker E, Eggen AE, Lund E. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer. 2004;112(1):130-134. (Pubitemid 39249500)
145. Lippman M, Monaco ME, Bolan G. Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res. 1977;37(6):1901-1907. (Pubitemid 8095209)
146. Lemon FlM, Wotiz HH, Parsons L, Mozden PJ. Reduced estriol excretion in patients with breast cancer prior to endocrine therapy. JAMA. 1966;196(13):1128-1136
147. Marmorston J, Fowley LG, Myers SM, Stem F, Hopkins CE. II. Urinary excretion of estrone, estradiol and estriol by patients wilh breast cancer and benign breast disease. Am J Obstet Gynecol. 1965;92:460-467.
148. Ottosson UB, Johansson BG, von Schoultz B. Subtractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone, Am J Obstet Gynecol. 1985;151(6):746-750. (Pubitemid 15237621)
149. Minshall RD, Stanczyk FZ, Miyagawa K, et al. Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys. J Clin Endocrinol Metab. 1998;83(2):649-659. (Pubitemid 28496553)
150. Mishra RG, Hermsmeyer RK, Miyagawas K, et al. Medroxy-progesterone acetate and dihydrotestosterone induce coronary hyperreactivity in intact male rhesus monkeys. J Clin Endocrinol Metab. 2005;90(6):3706-3714. (Pubitemid 41014346)
151. Miyagawa K, Roöch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med. 1997;3(3):324-327. (Pubitemid 27112931)
152. Adams MR, Register TC, Golden DL, Wagner JD, Williams J. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17(1):217-221. (Pubitemid 27057346)
153. Saarikoski S, Yliskoski M, Penttilä I. Sequential use of norethisterone and natural progesterone in pre-menopausal bleeding disorders. Maturitas. 1990;12(2):89-97. (Pubitemid 20188928)
154. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1995;273(3):199-208.
155. Fåhraeus L, Larsson-Cohn U, Wallentin L. L-norgestrel and progesterone have different influences on plasma lipoproteins. Eur J Clin Invest. 1983;13(6):447-453. (Pubitemid 14248742)
156. Larsson-Cohn U, Fåhraeus L, Wallentin L, Zador G. Lipoprotein changes may be minimized by proper composition of a combined oral contraceptive. Fertil Steril. 1981;35(2):172-179. (Pubitemid 11137719)
157. Ottosson UB. Oral progesterone and estrogen/progestogen therapy. Effects of natural and synthetic hormones on subfractions of HDL cholesterol and liver proteins. Acta Obstet Gynecol Scand Suppl. 1984;127:1-37. (Pubitemid 15189278)
158. Mälkönen M, Manninen V, Hirvonen E. Effects of danazol and lynestrenol on serum lipoproteins in endometriosis. Clin Pharmacol Ther. 1980;28(5):602-604. (Pubitemid 11254158)
159. Hirvonen E, Malkonen M, Manninen V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med. 1981;304(10):560-563. (Pubitemid 11142461)
160. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292(13):1573-1580. (Pubitemid 39314963)
161. Canonico M, Oger E, Plu-Burcau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840-845. (Pubitemid 46294724)
162. Rosano GM, Webb CM, Chierchia S, et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol. 2000;36(7):2154-2159.
163. Miller VT, Muesing RA, LaRosa JC, Stoy DB, Phillips EA, Stillman RJ, Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subtractions, and apolipoprotein A-1. Obstet Gynecol. 1991;77(2):235-240.
164. Levine RL, Chen SJ, Durand J, Chen YF, Oparil S. Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. Circulation. 1996;94(9):2221-2227. (Pubitemid 26360517)
165. Otsuki M, Saito H, Xu X, et al. Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2001;21(2):243-248. (Pubitemid 32125373)
166. Register TC, Adams MR, Golden DL, Clarkson TB. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol. 1998;18(7):1164-1171. (Pubitemid 28323602)
167. Wagner JD, Martino MA, Jayo MJ, Anthony MS, Clarkson TB, Cefalu WT. The effects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically postmenopausal cynomolgus monkeys. Metabolism. 1996;45(10):1254-1262. (Pubitemid 26337672)
168. Lindheim SR, Presser SC, Ditkoff EC, Vijod MA, Stanczyk FZ, Lobo RA. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril. 1993;60(4):664-667. (Pubitemid 23298511)
169. Spencer CP, Godsland IF, Cooper AJ, Ross D, Whitehead MI, Stevenson JC. Effects of oral and transdermal 17β-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. Metabolism. 2000;49(6):742-747. (Pubitemid 30354581)
170. Godsland IF, Gangar K, Walton C, et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism. 1993;42(7):846-853. (Pubitemid 23207112)
171. Feeman WE Jr. Thrombotic stroke in an otherwise healthy middle-aged female related to the use of continuous-combined conjugated equine estrogens and medroxyprogesterone acetate. J Gend Specif Med. 2000;3(8):62-64.
172. Jeanes HL, Wanikiat P, Sharif I, Gray GA. Medroxyprogesterone acetate inhibits the cardioprotective effect of estrogen in experimental ischemia-reperfusion injury. Menopause. 2006;13(1):80-86. (Pubitemid 43755900)
173. Jensen J, Riis BJ, Strøm V, Nilas L, Christiansen C. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol. 1987;156(1):66-71. (Pubitemid 17001090)
174. Williams JK, Honoré EK, Washburn SA, Clarkson TB. Effects of hormone replacement on therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol. 1994;24(7):1757-1761. (Pubitemid 24369203)
175. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis. 1990;10(6):1051-1057.
176. Bolaji H, Grimes H, Mortimer G, Tallon DF, Fottrell PF, O'Dwyer EM. Low-dose progesterone therapy in oestrogenised postmenopausal women: effects on plasma lipids, lipoproteins and liver function parameters. Eur J Obstet Gynecol Reprod Biol. 1993;48(1):61-68. (Pubitemid 23067115)
177. Morey AK, Pedram A, Razandi VI, et al. Estrogen and progesterone inhibit vascular smooth muscle proliferation. Endocrinology. 1997;138(8):3330-3339. (Pubitemid 27345686)
178. Lee WS, Harder JA, Yoshizumi M, Lee ME, Haber E. Progesterone inhibits arterial smooth muscle cell proliferation. Nat Med. 1997;3(9):1005-1008. (Pubitemid 27391955)
179. Minshall RD, Miyagawa K, Chadwick CC, Novy MJ, Hermsmeyer K. In vitro modulation of primate coronary vascular muscle cell reactivity by ovarian steroid hormones. FASEB J. 1998;12(13):1419-1429. (Pubitemid 28475584)
180. Minshall RD, Pavenik D, Halushka PV, Hermsmeyer RK. Progesterone regulation of vascular thromboxane A2 receptors in rhesus monkeys. Am J Physiol Heart Circ Physiol. 2001;281(4):H1498-H1507. (Pubitemid 32948193)
181. Houser SL, Aretz HT, Quist WC, Chang Y, Schreiber AD. Serum lipids and arterial plaque load are altered independently with high-dose progesterone in hypercholesterolemic male rabbits. Cardiovasc Pathol. 2000;9(6):317-322. (Pubitemid 32012559)
182. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol. 1997;17(11):3071-3078. (Pubitemid 28016061)
183. Martinez C, Basurto L, Zarate A, Saucedo R, Gaminio H, Collazo J. Transdemial estradiol does not impair hemostatic biomarkers in postmenopausal women. Maturitas. 2005;50(1):39-43. (Pubitemid 39601707)
184. Oger E, Alhenc-Gelas M, Laeut K, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol. 2003;23(9):1671-1676. (Pubitemid 37108215)
185. Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdemial contraceptive system users. Obstet Gynecol. 2007;109(2 pt 1):339-346. (Pubitemid 46197426)
186. Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives contain norgestimate and 35 μg of ethinyl estradiol. Contraception. 2006;73(3):223-228. (Pubitemid 43202170)
187. Hellman I, Yoshida K, Zurnoff B, Levin J, Kream J, Fukushima DK. The effect of medroxyprogesterone acetate on the pituitary-adrenal axis, J Clin Endocrinol Metab. 1976;42(5):912-917.
188. Davila E, Vogel CL, East D, Cairns V, Hilscnbeck S. Clinical trial of high-dose oral medroxyprogesteorne acetate in the treatment of metastatic breast cancer and review of the literature. Cancer. 1988;61(11):2161-2167. (Pubitemid 18133940)
189. Corvol P, Elkik F, Feneant M, et al. Effect of progesterone and progestins on water and salt metabolism. In: Bardin CW, Milgrom E, Mauvais-Jarvis P, eds. Progesterone and Progestins. New York, NY: Raven Press; 1983;1979-1986.
190. Rylance PB, Brincat M, Lafferty K, et al. Natural progesterone and antihypertensive action. Bri Med J. 1985(6461);290:13-14. (Pubitemid 15075974)
191. Elkind-Hirsch KE, Sherman LD, Malinak R. Hormone replacement therapy alters insulin sensitivity in young women with premature ovarian failure. J Clin Endocrinol Metab. 1993;76(2):472-475. (Pubitemid 23073076)
192. Tzingounis VA, Aksu MF, Greenblatt RB. Estriol in the management of the menopause. JAMA. 1978;239(16):1638-1641. (Pubitemid 8317745)
193. Yang TS, Tsan SH, Chang SP, Ng HT. Efficacy and safety of estriol replacement therapy for climacteric women. Chin Med J (Taipei). 1995;55:386-391.
194. Perović D, Kopajtic B, Stanković T. Treatment of climacteric complaints with oestriol. Arzneimittel-Forschung. 1975;25(6):962-964.
195. van der Linden MC, Gerretsen G, Brandhorst MS, Ooms EC, Kremer CM, Doesburg WH. The effect of estriol on the cytology of urethra and vagina in postmenopausal women with genito-urinary symptoms. Eur J Obstet Gynecol Reprod Biol. 1993;51(1):29-33. (Pubitemid 23340889)
196. Cardoza L, Rekers H, Tapp A, et al. Oestriol in the treatment of postmenopausal urgency: a multicentre study. Maturitas. 1993;18(1):47-53. (Pubitemid 24037142)